Laurence Gladieff

9.7k total citations
135 papers, 1.9k citations indexed

About

Laurence Gladieff is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Laurence Gladieff has authored 135 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Reproductive Medicine, 56 papers in Oncology and 41 papers in Surgery. Recurrent topics in Laurence Gladieff's work include Ovarian cancer diagnosis and treatment (69 papers), Intraperitoneal and Appendiceal Malignancies (30 papers) and Endometrial and Cervical Cancer Treatments (21 papers). Laurence Gladieff is often cited by papers focused on Ovarian cancer diagnosis and treatment (69 papers), Intraperitoneal and Appendiceal Malignancies (30 papers) and Endometrial and Cervical Cancer Treatments (21 papers). Laurence Gladieff collaborates with scholars based in France, Italy and United States. Laurence Gladieff's co-authors include Gwénaël Ferron, Alejandra Martínez, Florence Dalenc, Eliane Mery-Lamarche, Étienne Chatelut, Éric Pujade-Lauraine, Anne Floquet, Henri Roché, Michel Fabbro and Marion Montastruc and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Laurence Gladieff

121 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurence Gladieff France	24	752	657	531	421	242	135	1.9k
Barbara Schmalfeldt Germany	23	884 1.2×	1.3k 2.0×	719 1.4×	481 1.1×	189 0.8×	92	2.1k
Frédèric Selle France	24	1.4k 1.9×	1.1k 1.7×	940 1.8×	436 1.0×	599 2.5×	127	2.4k
Gina Mantia-Smaldone United States	19	751 1.0×	758 1.2×	271 0.5×	353 0.8×	140 0.6×	56	1.8k
Kristin K. Zorn United States	20	335 0.4×	662 1.0×	276 0.5×	440 1.0×	118 0.5×	59	1.4k
G. Scott Rose United States	27	494 0.7×	1.0k 1.6×	698 1.3×	924 2.2×	233 1.0×	68	2.1k
Philippe Follana France	20	1.1k 1.4×	1.3k 1.9×	649 1.2×	255 0.6×	523 2.2×	83	2.3k
Giovanna Scarfone Italy	28	844 1.1×	1.6k 2.4×	771 1.5×	987 2.3×	287 1.2×	83	2.6k
George J. Olt United States	16	767 1.0×	902 1.4×	680 1.3×	941 2.2×	297 1.2×	38	2.3k
Pınar Saip Türkiye	21	606 0.8×	316 0.5×	337 0.6×	169 0.4×	520 2.1×	115	1.6k
Sudha Sundar United Kingdom	21	373 0.5×	661 1.0×	317 0.6×	686 1.6×	134 0.6×	103	1.5k

Countries citing papers authored by Laurence Gladieff

Since Specialization

Citations

This map shows the geographic impact of Laurence Gladieff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Gladieff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Gladieff more than expected).

Fields of papers citing papers by Laurence Gladieff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Gladieff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Gladieff. The network helps show where Laurence Gladieff may publish in the future.

Co-authorship network of co-authors of Laurence Gladieff

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Gladieff. A scholar is included among the top collaborators of Laurence Gladieff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Gladieff. Laurence Gladieff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zemmour, Christophe, Manuel Rodrigues, Isabelle Ray‐Coquard, et al.. (2025). PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network. The Oncologist. 30(5).

Olawaiye, Alexander, Jae‐Weon Kim, Erin Bishop, et al.. (2024). Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. Journal of Gynecologic Oncology. 35(4). e111–e111. 4 indexed citations

Pautier, Patricia, Catherine Genestie, Laurence Gladieff, et al.. (2023). Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer du col de l'utérus avancé. Bulletin du Cancer. 110(6). 6S44–6S50.

Classe, Jean‐Marc, Pierre Méeus, Éric Leblanc, et al.. (2023). #876 Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the chipor randomised phase III trial. A29.1–A29. 4 indexed citations

Gilhodes, Julia, Bastien Cabarrou, Thomas Filleron, et al.. (2023). Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients. International Journal of Molecular Sciences. 24(18). 14348–14348. 1 indexed citations

Falandry, Claire, Fanny Pommeret, Laurence Gladieff, et al.. (2022). Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. The Lancet Healthy Longevity. 3(3). e176–e185. 7 indexed citations

Gladieff, Laurence, et al.. (2021). Pocket memo based on the ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma: definition of prognostic risk groups. International Journal of Gynecological Cancer. 31(12). ijgc–2021. 3 indexed citations

Lavoué, Vincent, et al.. (2020). Onco-gynecologic surgery in the COVID-19 era: Risks and precautions—A position paper from FRANCOGYN, SCGP, SFCO, and SFOG. Journal of Gynecology Obstetrics and Human Reproduction. 49(7). 101787–101787. 5 indexed citations

You, Benoît, Pierre‐Adrien Bolze, Jean‐Pierre Lotz, et al.. (2020). Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. Journal of Clinical Oncology. 38(27). 3129–3137. 75 indexed citations

10.

Selle, Frédèric, Pierre-Étienne Heudel, Anne‐Claire Hardy‐Bessard, et al.. (2020). GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer. Anticancer Research. 40(7). 3939–3945. 7 indexed citations

11.

Gladieff, Laurence, Fanny Le Du, Dominique Berton-Rigaud, et al.. (2020). 827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc). Annals of Oncology. 31. S623–S624. 1 indexed citations

12.

Jacot, William, Florence Dalenc, Evelyne Lopez‐Crapez, et al.. (2019). PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Breast Cancer Research and Treatment. 177(3). 659–667. 18 indexed citations

13.

Selle, Frédèric, Pierre-Étienne Heudel, Youssef Tazi, et al.. (2017). Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study. Annals of Oncology. 28. v344–v345. 1 indexed citations

14.

Sibaud, V., Nicole R. LeBoeuf, Henri Roché, et al.. (2016). Dermatological adverse events with taxane chemotherapy. European Journal of Dermatology. 26(5). 427–443. 153 indexed citations

15.

Regnault, M. Masson, S. Boulinguez, É. Tournier, et al.. (2015). Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature. Dermatology. 231(4). 312–318. 13 indexed citations

16.

Ferron, Gwénaël, Alejandra Martínez, Laurence Gladieff, et al.. (2014). Adherence to Guidelines in Gynecologic Cancer Surgery. International Journal of Gynecological Cancer. 24(9). 1675–1678. 14 indexed citations

17.

Lecarpentier, Julie, Catherine Noguès, Emmanuelle Mouret‐Fourme, et al.. (2011). Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Research and Treatment. 130(3). 927–938. 30 indexed citations

18.

Julian‐Reynier, Claire, Anne‐Déborah Bouhnik, Christine Lasset, et al.. (2010). Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genetics in Medicine. 12(12). 801–807. 30 indexed citations

19.

Aziza, R., et al.. (2001). Assessing the quality of Claudius-Regaud Institute patients' medical records. Bulletin du Cancer. 88(8). 793–803.

20.

Aziza, R., et al.. (2001). Evaluation de la qualité du dossier du patient à l'Institut Claudius-Regaud. Bulletin du Cancer. 88(8). 793–803. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact